
Regeneron's Livsayis (cemdisiran) gains FDA approval for adults with antibody-positive generalized myasthenia gravis, dosed four times a year.
London-GlaxoSmithKline is proposing to cut more than 2,000 jobs from its worldwide workforce of 100,000 as it seeks to generate the promised savings from its merger.
over 25 years ago
Decision Making at Digital Speedover 25 years ago
Generics: Streamline and Stimulateover 25 years ago
Grace Under Fireover 25 years ago
Get Ready to Merge or Divergeover 25 years ago
Pharma's Quantum Shuffleover 25 years ago
Science-Driven Marketing





